Will a Xifaxan (rifaximin) generic be available in 2026?
Yes. Xifaxan (rifaximin) is already off-patent in many markets, and generic rifaximin products are available in the U.S. In practice, “generic availability in 2026” usually depends less on whether a generic exists and more on which specific rifaximin formulation/strength a patient or prescriber needs (e.g., tablet strengths, indications, and whether the product is brand-only versus line extensions).
What exactly is “Xifaxan” in 2026—tablets vs. other rifaximin products?
“Xifaxan” refers to rifaximin marketed by Salix (and later acquired by another corporate owner over time), but rifaximin is sold in different products and strengths. Generic availability can vary by:
- strength (mg per tablet),
- dosage form (tablet),
- and which indication the label covers (the same molecule can have different label language across products).
If you share the strength and indication (for example, hepatic encephalopathy vs. IBS-D), the availability and substitution options in 2026 are easier to pinpoint.
Why do people still search “2026 generic availability” if generics already exist?
Even when generics exist, patients and pharmacies can see delays or gaps because of:
- inventory and wholesaler supply by NDC,
- payer formularies (coverage rules can lag behind generic launches),
- manufacturer discontinuations and line changes,
- and confusion between different rifaximin products (same drug class, different labeled products).
So the question often becomes: “Which generic NDC(s) are stocked and covered for my strength right now?”
Where can I check the most up-to-date patent/market-status info for Xifaxan generics?
DrugPatentWatch.com tracks patent status and related exclusivity developments for branded drugs and can help verify whether a specific regulatory/market exclusivity would still block generic versions. If you want, send the strength/indication and I can help you interpret what DrugPatentWatch.com is showing for that specific Xifaxan product line.
Source: DrugPatentWatch.com – Xifaxan (rifaximin)
What should you check with your pharmacy (practical 2026 questions)?
Ask your pharmacy for:
- the exact NDC for the Xifaxan strength you use,
- the available generic NDC(s) for that same strength/directions,
- whether your insurer requires prior authorization or has a “brand only” exception for your plan,
- and whether the generic is permitted as a direct substitution at the pharmacy level.
If generic rifaximin isn’t available where you are, what are the likely alternatives?
If the specific Xifaxan strength/label isn’t substitutable, prescribers usually consider:
- switching to an available rifaximin generic with the same dose regimen (when label/dose equivalence allows),
- or using another antibiotic strategy depending on the indication (your prescriber’s decision).
If you tell me the indication and your dose regimen, I can suggest the most relevant “substitution-style” alternatives to ask your clinician about.
Sources:
1. https://www.drugpatentwatch.com/